Mechanism of volatile oil from Alpinia oxyphylla in treating Alzheimer's disease based on GC-MS and network pharmacology.
10.19540/j.cnki.cjcmm.20210301.401
- Author:
Wen-Jing LI
1
;
Shuai XIAO
1
;
Qin ZHENG
1
;
Li-Yun ZHU
1
;
Ming-Xia ZHANG
1
;
Ming YANG
1
;
Yue YAN
1
;
Zi-Yi WANG
1
Author Information
1. State Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Key Laboratory of Modern Preparation of Traditional Chinese Medicine under Ministry of Education, Jiangxi University of Traditional Chinese Medicine Nanchang 330004, China.
- Publication Type:Journal Article
- Keywords:
Alzheimer′s disease;
GC-MS;
mechanism;
network pharmacology;
volatile oil from Alpinia oxyphylla
- MeSH:
Alpinia;
Alzheimer Disease/genetics*;
Drugs, Chinese Herbal;
Gas Chromatography-Mass Spectrometry;
Humans;
Molecular Docking Simulation;
Oils, Volatile
- From:
China Journal of Chinese Materia Medica
2021;46(12):3052-3057
- CountryChina
- Language:Chinese
-
Abstract:
To study the material basis and mechanism of volatile oil from Alpinia oxyphylla in treating Alzheimer's disease(AD) based on GC-MS and network pharmacology. Ingredients of volatile oil from A.oxyphylla were analyzed by GC-MS. Targets of those ingredients were obtained through Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP). Relevant targets of AD were obtained through such databases as DrugBank, STITCH, OMIM. Intersection targets of ingredients and diseases were obtained by Online Venny map, and PPI network was established by STRING to screen out core targets. Gene ontology(GO) functional enrichment analysis and KEGG pathway enrichment analysis were performed by DAVID. The "ingredients-target-pathway" network was constructed by software Cytoscape 3.8.1 to screen out potential active ingredients of volatile oil from A.oxyphylla in the treatment of AD. The results showed that a total of 6 active ingredients were screened from the volatile oil of A.oxyphylla by GC-MS, 17 targets corresponding to 6 active ingredients were found in TCMSP database, and 3 448 AD targets were found in DrugBank database. "Ingredients-target-pathway" network and PPI network showed there were 4 potential active ingredients in the treatment of AD and 4 core targets. GO analysis and KEGG analysis showed 34(P<0.05) and 5(P<0.05) pathways, respectively, including nerve ligand receptor interaction, calcium signaling pathway, cholinergic synapse and 5-hydroxytryptaminergic synapse. This suggested that volatile oil from A.oxyphylla could synergistically treat AD by regulating calcium balance, cholinergic balance and phosphorylation. This study provided reference and guidance for further study of volatile oil from A.oxyphylla in the treatment of AD.
